Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide ... is helping people shed weight, drugs like Ozempic and Mounjaro were flying off pharmacy shelves.

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Nearly two in three people with fatty liver disease lost some of the liver fat and inflammation after using semaglutide 2.4 ...

We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." ...

The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

Based on these data, we look forward ... treated with semaglutide 2.4 mg compared to placebo. These were supportive secondary endpoints, not controlled for multiplicity.1 Safety endpoints ...

Findings showed a 13.6% reduction in body weight in the semaglutide ... and look forward to working with regulatory authorities on what would be the first oral [glucagon-like peptide-1] treatment ...